Unfortunately, there are scientists who have little knowledge of the trial data. Read this: Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling? Ethan Chen, Alexander L Ling, David A Reardon, E Antonio Chiocca